Combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).
Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); Age ≥ 75 years; hot failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
• indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
• Treatment of diabetes insipidus (excluding nephrogenic diabetes insipidus).
• Control of bleeding esophageal varices.
Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
Letermovir is indicated for prophylaxis of CMV disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].
Consideration should be given to official guidance on the appropriate use of antiviral agents.
Registration
NCE
OLIMEL N12E
Glucose With Calcium Solution, Amino Acid With Electrolytes Solution And Lipid Emulsion,Glucose With Calcium Solution,Amino Acid With Electrolytes Solution,Lipid Emulsion
Glucose With Calcium Solution, Amino Acid With Electrolytes Solution And Lipid Emulsion,Glucose With Calcium Solution,Amino Acid With Electrolytes Solution,Lipid Emulsion
SFDA Approved Use
OLIMEL N12E is indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
